Reha Technology AG Receives Major Financing by International Healthcare Investor HBM BioCapital II
OLTEN, Switzerland, January 18, 2013 /PRNewswire/ --
Reha Technology AG announced today the closing of financing by HBM BioCapital II LP; a private equity partnership advised by HBM Partners AG, Switzerland.
Reha Technology AG, a Swiss company, designs, manufactures and globally distributes advanced robotic-assisted systems for neurorehabilitation. The development for the patented G-EO System™ which is the world's first and only gait rehabilitation device with the ability to simulate stair climbing up and down, started in 2007 in Bolzano, Italy. The company began operations in Switzerland in 2012. Since then, a worldwide distributor network and operations in the United States have been established. The expansion of the global network and the launch of additional products are the primary goals for 2013.
In connection with the financing, HBM BioCapital II acquired a significant minority stake in Reha Technology AG. The capital will be used to further expand Reha Technology's business on a worldwide basis. HBM is a major European healthcare investor with assets of around $800 million under management. HBM supports pharma, medical technology and diagnostics companies in their worldwide business expansion.
René Trost, CEO of Reha Technology AG, comments: "We are proud that we were able to attract a major healthcare investor as a new shareholder for Reha Technology. With the support of HBM, we will be able to substantially expand and grow our business of selling the most advanced rehabilitation robotic systems to customers around the world."
About Reha Technology AG
Reha Technology AG improves the quality of life for all those who have been injured or disabled by illness or accident. To achieve this goal, the company uses research and development of new technologies in robotics focusing on robotic assisted rehabilitation and makes the newest and most effective technologies available for medical rehabilitation devices. FOR A BETTER LIFE.
About HBM Partners
HBM Partners is among the global leaders in healthcare-focused investing with approximately $800 million under management. HBM focuses on development-stage, growth and buy-out financings of private companies as well as investments in public companies. HBM Partners advises HBM Healthcare Investments AG, HBM BioCapital I & II and further specialized private-equity and public-equity funds. HBM has been an active contributor to value creation in portfolio companies, generating over 40 trade sales and IPOs since inception. For more information visit: http://www.hbmpartners.com.
SOURCE REHA Technology AG
More by this Source
Reha Technology AG recibe una importante financiación de HBM BioCapital II
19 Jan, 2013, 17:18 GMT
Journalists and Bloggers
Visit PR Newswire for Journalists for releases, photos and customised feeds just for Media.
View and download archived video content distributed by MultiVu on The Digital Center.
Until you hear the full story, why would you invest?
Making sound investment decisions can be difficult. You can study the figures and read the analyst recommendations, but how do you really know the story behind company strategy? How can you get answers to your questions?
The Private Investor Network helps you to reach an informed decision on the stocks you pick. Interactive presentations from UK listed companies give you the kind of access previously enjoyed only by the big fund managers. And with keynote speeches from industry experts, downloadable content and an investor lounge where you can swap tips with your peers, you can invest with confidence.
For more information, and to register for FREE, visit us at www.privateinvestornetwork.co.uk
Get content for your website
Enhance your website's or blog's content with PR Newswire's customised real-time news feeds.
Contact PR Newswire
Send us an email at MarketingUK@prnewswire.co.uk or call us at +44 (0)20 7454 5382
Become a PR Newswire client
Request more information about PR Newswire products & services or call us at +44 (0)20 7454 5382